
    
      This clinical trial is a single centre phase Ib open dose adjustment study with respect to
      the dose of C-Tb combined with a double blind randomised, split-body comparison of
      unpreserved C-Tb and C-Tb preserved with 0.5% phenol (each patient receives the unpreserved
      version in one arm and the preserved version in the other arm).
    
  